TerminatedNot applicableNCT03694431
Official study title

Comparative Trial of Home-Based Palliative Care

Study summary

Background: To effectively alleviate suffering and improve quality of life for patients with serious illness and their caregivers, palliative care (PC) services must be offered across multiple settings. Research is needed to determine how best to optimize home-based palliative care (HBPC) services to meet the needs of individuals with high symptom burden and functional limitations. Aim: The investigators will compare a standard HBPC model that includes routine home visits by a nurse and provider with a more efficient tech-supported HBPC model that promotes timely inter-professional team coordination via synchronous video consultation with the provider while the nurse is in the patient's home. The investigators hypothesize that tech-supported HBPC will be as effective as standard HBPC. Design: Cluster randomized trial. Registered nurses (n\~130) will be randomly assigned to the tech-supported or standard HBPC model so that half of the patient-caregiver dyads will receive one of the two models. Setting/Participants: Kaiser Permanente (15 Southern California and Oregon sites). Patients (n=10,000) with any serious illness and a prognosis of 1-2 years and their caregivers (n=4,800) Methods: Patients and caregivers will receive standard PC services: comprehensive needs assessment and care planning, pain and symptom management, education/skills training, medication management, emotional/spiritual support; care coordination, referral to other services, and 24/7 phone assistance. Results: Primary patient outcomes: symptom improvement at 1 month and days spent at home in the last six months of life; caregiver outcome: perception of preparedness for caregiving. Conclusion: Should the more efficient tech-supported HBPC model achieves comparable improvements in outcomes that matter most to patients and caregivers, this would have a lasting impact on PC practice and policy.

Ask AI to explain this study
Start here

Key things to know

Main goalSupportive Care

This describes the study’s primary purpose.

What is being studiedTech-supported HBPC and Standard HBPC

The study team can explain what participation involves.

Who it may be forCancer · Chronic Obstructive Pulmonary Disease

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Feb 20, 2020 · Source: ClinicalTrials.gov

Is enrollment open?Terminated

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?2 U.S. locations

Locations may change over time.

Who runs it?Kaiser Permanente

Study sponsor

01
Study overview

What this study is about

Purpose
Supportive Care
Study type
Interventional
Phase
Not applicable
Sponsor
Kaiser Permanente
Interventions being studied
Other: Tech-supported HBPC; Other: Standard HBPC
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • Patient
  • Serious illness with 12-24 month life expectancy
  • Homebound
  • Need for skilled nursing care (only at KP Southern California)
  • English or Spanish speakers Patient
Reasons someone may not be able to joinExclusion criteria
  • \- Currently receiving HBPC Caregiver Inclusion Criteria:
  • Non-professional family, friend or other caregiver
  • English or Spanish speakers

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Kaiser Permanente Southern CaliforniaPasadena, California
  • Kaiser Permanente NorthwestPortland, Oregon

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Feb 20, 2020. Always confirm current availability with the study team.

View original record ↗